Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
QDEL 
Quidel Corporation (QDEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/22/2025: QDEL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $37.67
1 Year Target Price $37.67
| 3 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.85% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.97B USD | Price to earnings Ratio - | 1Y Target Price 37.67 |
Price to earnings Ratio - | 1Y Target Price 37.67 | ||
Volume (30-day avg) 8 | Beta 0.58 | 52 Weeks Range 19.50 - 49.45 | Updated Date 12/22/2025 |
52 Weeks Range 19.50 - 49.45 | Updated Date 12/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -17.41 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -43.45% | Operating Margin (TTM) 6.67% |
Management Effectiveness
Return on Assets (TTM) 1.42% | Return on Equity (TTM) -45.17% |
Valuation
Trailing PE - | Forward PE 10.94 | Enterprise Value 4711638767 | Price to Sales(TTM) 0.72 |
Enterprise Value 4711638767 | Price to Sales(TTM) 0.72 | ||
Enterprise Value to Revenue 1.74 | Enterprise Value to EBITDA 22.78 | Shares Outstanding 67931540 | Shares Floating 62632880 |
Shares Outstanding 67931540 | Shares Floating 62632880 | ||
Percent Insiders 0.94 | Percent Institutions 123.33 |
Upturn AI SWOT
Quidel Corporation
Company Overview
History and Background
Quidel Corporation, founded in 1979, is a leading developer, manufacturer, and marketer of rapid diagnostic solutions. Initially focused on infectious disease diagnostics, Quidel has expanded its portfolio through organic growth and strategic acquisitions to include a broad range of diagnostic tests for various medical conditions. A significant milestone was its merger with Qiagen, which was later terminated, and its subsequent acquisition of Thermo Fisher Scientific's Point-of-Care Diagnostic instruments business.
Core Business Areas
- Integrated Diagnostic Solutions: This segment encompasses Quidel's broad range of diagnostic instruments and assay menus. It includes solutions for immunoassay, molecular, and other diagnostic testing platforms used in point-of-care settings, hospitals, and reference laboratories. Products cover infectious diseases, women's health, cardiac markers, and more.
- Standalone Diagnostic Products: This segment focuses on Quidel's rapid diagnostic tests that do not necessarily require integration with a specific instrument platform. These are often single-use tests for various medical conditions, including infectious diseases like COVID-19, influenza, strep throat, and pregnancy tests.
Leadership and Structure
Quidel is led by a management team responsible for strategy, operations, research and development, and sales and marketing. The company is structured into business units that align with its core product lines and market segments. Specific leadership details, including names and titles, are subject to change and are best found on the company's official investor relations website.
Top Products and Market Share
Key Offerings
- Trio+ (Molecular Diagnostic Instrument): A highly sensitive, multiplex molecular diagnostic platform for infectious disease detection. Competitors include Roche Diagnostics, Abbott Laboratories, and Hologic.
- Sofia 2 (Fluorescent Immunoassay Analyzer): A versatile point-of-care instrument that utilizes immunofluorescence for rapid detection of various infectious diseases. Competitors include Abbott Laboratories, BD (Becton, Dickinson and Company), and Siemens Healthineers.
- Quidel QuickVue (Rapid Antigen and Antibody Tests): A range of rapid diagnostic tests for infectious diseases (e.g., COVID-19, Influenza A+B, Strep A) and other conditions. These are widely used in point-of-care settings. Competitors include Abbott Laboratories, Binx Health, and EKF Diagnostics.
- Thyroid Stimulating Hormone (TSH) Test: A diagnostic test used in immunoassay platforms to detect thyroid dysfunction. Competitors include Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers.
Market Dynamics
Industry Overview
The diagnostic industry is characterized by rapid technological advancements, increasing demand for point-of-care testing, and a growing focus on infectious disease and chronic condition management. The COVID-19 pandemic significantly boosted the demand for rapid diagnostic tests, a trend that continues to influence market dynamics.
Positioning
Quidel is positioned as a leading provider of rapid diagnostic solutions, with a strong emphasis on point-of-care testing. Its competitive advantages lie in its broad product portfolio, established distribution channels, and its ability to develop and market rapid, accurate diagnostic tests for critical health concerns. The company has a significant presence in infectious disease diagnostics.
Total Addressable Market (TAM)
The global in-vitro diagnostics (IVD) market is substantial and growing, estimated to be in the tens of billions of US dollars annually, with projections indicating continued expansion. Quidel participates in various segments of this market, including infectious disease diagnostics, immunoassay, and molecular diagnostics. Its positioning is strong within the point-of-care and rapid diagnostics segments of this TAM.
Upturn SWOT Analysis
Strengths
- Strong portfolio of rapid diagnostic tests for infectious diseases.
- Established relationships with healthcare providers and laboratories.
- Reputation for accuracy and reliability in diagnostic testing.
- Experience in navigating regulatory approvals for diagnostic products.
Weaknesses
- Dependence on specific product lines, especially in times of high demand for certain tests.
- Potential for intense competition from larger, diversified healthcare companies.
- Integration challenges following acquisitions.
Opportunities
- Expansion into new diagnostic areas and emerging diseases.
- Leveraging technological advancements for more sophisticated molecular diagnostics.
- Growing global demand for accessible and rapid diagnostic solutions.
- Strategic partnerships and collaborations to broaden market reach.
Threats
- Intensifying competition and price pressures.
- Changes in healthcare reimbursement policies.
- Regulatory changes and challenges in obtaining approvals.
- Emergence of new diseases or pandemics that require rapid adaptation.
- Supply chain disruptions impacting manufacturing and distribution.
Competitors and Market Share
Key Competitors
- Abbott Laboratories (ABT)
- Roche Diagnostics (RHHBY)
- BD (Becton, Dickinson and Company) (BDX)
- Siemens Healthineers (SEMHF)
- Hologic (HOLX)
Competitive Landscape
Quidel faces intense competition from large, diversified healthcare conglomerates and specialized diagnostic companies. Its competitive advantages lie in its agility in developing rapid tests and its focus on specific diagnostic niches. However, larger competitors often have greater R&D budgets and broader market reach, which can pose a challenge.
Major Acquisitions
Thermo Fisher Scientific's Point-of-Care Diagnostic instruments business
- Year: 2023
- Acquisition Price (USD millions):
- Strategic Rationale: To expand Quidel's portfolio of point-of-care diagnostic instruments and accelerate its growth in this key market segment.
Growth Trajectory and Initiatives
Historical Growth: Quidel experienced significant growth during the COVID-19 pandemic due to high demand for its diagnostic tests. Prior to that, growth was more moderate, driven by its expanding portfolio and market penetration. Post-pandemic, growth is expected to be more normalized and dependent on new product introductions and market expansion.
Future Projections: Future growth projections for Quidel are influenced by analyst expectations regarding the continued demand for diagnostic tests, success of new product launches, and its ability to adapt to evolving market needs. Analysts often provide revenue and EPS growth estimates.
Recent Initiatives: Recent initiatives may include the integration of acquired businesses, expansion of its molecular diagnostic offerings, and continued investment in research and development to address emerging health threats. Strategic partnerships and global market expansion are also key initiatives.
Summary
Quidel Corporation is a significant player in the rapid diagnostic solutions market, particularly strong in infectious disease testing. Its agility and product innovation are key strengths, evidenced by its response to the COVID-19 pandemic. However, it faces intense competition and the challenge of normalizing demand post-pandemic. Strategic acquisitions and continued R&D are crucial for sustained growth and market position.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Quidel Corporation Investor Relations
- SEC Filings (10-K, 10-Q)
- Financial News Outlets (e.g., Wall Street Journal, Bloomberg)
- Market Research Reports on the IVD industry
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. Market share data and financial projections are estimates and subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Quidel Corporation
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 1991-02-01 | President, CEO & Director Mr. Brian J. Blaser | ||
Sector Healthcare | Industry Medical Devices | Full time employees 6600 | Website https://www.quidelortho.com |
Full time employees 6600 | Website https://www.quidelortho.com | ||
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.